My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. - ADSs
(NQ:
NBTX
)
12.50
+2.30 (+22.55%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Sep 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanobiotix S.A. - ADSs
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Today 15:46 EDT
Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months survival.
Via
Benzinga
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
Today 10:19 EDT
Via
Benzinga
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Today 5:09 EDT
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 17, 2025
Via
Benzinga
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
September 17, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
September 12, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
August 27, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 26, 2025
Via
Benzinga
SelectQuote Posts Better-Than-Expected Results, Joins Nutex Health, NIO, MINISO Group And Other Big Stocks Moving Higher On Thursday
August 21, 2025
Via
Benzinga
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
July 07, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
June 10, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
May 28, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
May 21, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
May 14, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
May 12, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
May 05, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
April 30, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 14, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
April 02, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Earnings Scheduled For April 2, 2025
April 02, 2025
Via
Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
March 31, 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
March 27, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
March 20, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
March 18, 2025
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 17, 2025
Via
Benzinga
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
March 17, 2025
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
March 13, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 12, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
January 29, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.